Therapeutic options in multiple sclerosis: five new things.
Department of Neurology, University of Colorado, Denver, CO, USA. augusto.miravalle@ucdenver.edu
Augusto
A
Miravalle
John R
JR
Corboy
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers / Q000378:metabolism; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy*; D000069442:Natalizumab; D009416:Nerve Regeneration / Q000187:drug effects / Q000502:physiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D007155:Immunologic Factors; D000069442:Natalizumab